Identification, isolation, and structural characterization of novel forced degradation products of Ertugliflozin using advanced analytical techniques.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 Jun 2023
10 Jun 2023
Historique:
received:
15
01
2023
accepted:
31
05
2023
medline:
12
6
2023
pubmed:
11
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
The research elucidates the stress degradation behavior of Ertugliflozin, which is used for the treatment of type-2 diabetics. The degradation was conducted as per ICH guidelines and Ertugliflozin is relatively stable in thermal, photolytic, neutral, and alkaline hydrolysis conditions; however, considerable degradation was detected in acid hydrolysis and oxidative hydrolysis. Degradation products were identified by ultra-high-performance liquid chromatography-mass spectrometry, isolated by semi-preparative high-performance liquid chromatography, and structural characterization using high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy. Total four degradation products were identified and isolated in acid degradation, which are degradation products 1, 2, 3, and 4. Whereas in oxidative conditions, degradation product 5 was identified. All the five degradation products formed are novel, which was not reported earlier. This is the first time documented complete structural characterization of all five degradation products by using a hyphenated analytical technique. High-resolution mass, and nuclear magnetic resonance spectroscopy were used in the present study to get concrete confirmation of degradation products structures. The current method is also used to identify degradation products with shorter runtime in the future.
Identifiants
pubmed: 37301855
doi: 10.1038/s41598-023-36289-9
pii: 10.1038/s41598-023-36289-9
pmc: PMC10257675
doi:
Substances chimiques
ertugliflozin
6C282481IP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9472Informations de copyright
© 2023. The Author(s).
Références
Anal Biochem. 2019 Feb 15;567:112-116
pubmed: 30578763
Clin Pharmacol Drug Dev. 2019 Jul;8(5):619-627
pubmed: 30427588
Drug Metab Dispos. 2013 Feb;41(2):445-56
pubmed: 23169609
Front Endocrinol (Lausanne). 2017 Jan 24;8:6
pubmed: 28167928
Drug Des Devel Ther. 2017 Oct 03;11:2905-2919
pubmed: 29042751